Catalase activity and arsenic sensitivity in acute leukemia

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1976-1981

  Coe, Emma ^a,b   Schimmer, Aaron D ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chemotherapeutic approaches; Dysplasia; Myeloid leukemias; Neoplasia; Pharmacotherapeutics

Indexed keywords

ARSENIC TRIOXIDE; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; HYDROGEN PEROXIDE; PROMYELOCYTIC LEUKEMIA PROTEIN; REACTIVE OXYGEN METABOLITE; RETINOIC ACID RECEPTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

APOPTOSIS; ARSENICALS; CATALASE; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; TUMOR CELLS, CULTURED;

EID: 55049128272     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802353617     Document Type: Conference Paper

References (24)

1. Soignet, S. L., Maslak, P., Wang, Z. G., Jhanwar, S., Calleja, E. Dardashti, L. J. et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 339, pp. 1341-1348.
2. Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H. Calleja, E. et al. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 19, pp. 3852-3860.
3. Shen, Z. X., Chen, G. Q., Ni, J. H., Li, X. S., Xiong, S. M. Qiu, Q. Y. et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, pp. 3354-3360.
4. Mathews, V., George, B., Lakshmi, K. M., Viswabandya, A., Bajel, A. Balasubramanian, P. et al. (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood, 107, pp. 2627-2632.
5. Duprez, E., Saurin, A. J., Desterro, J. M., Lallemand-Breitenbach, V., Howe, K. Boddy, M. N. et al. (1999) SUMO-1 modification of the acute promyelocytic leukaemia protein PML: Implications for nuclear localisation. J Cell Sci, 112, pp. 381-393.
6. Kamitani, T., Kito, K., Nguyen, H. P., Wada, H., Fukuda-Kamitani, T. and Yeh, E. T. (1998) Identification of three major sentrinization sites in PML. J Biol Chem, 273, pp. 26675-26682.
7. Amadori, S., Fenaux, P., Ludwig, H., O'Dwyer, M. and Sanz, M. (2005) Use of arsenic trioxide in haematological malignancies: Insight into the clinical development of a novel agent. Curr Med Res Opin, 21, pp. 403-411.
8. Kumana, C. R., Au, W. Y., Lee, N. S., Kou, M., Mak, R. W. Lam, C. W. et al. (2002) Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol, 58, pp. 521-526.
9. Parmar, S., Rundhaugen, L. M., Boehlke, L., Riley, M., Nabhan, C. Raji, A. et al. (2004) Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res, 28, pp. 909-919.
10. Chen, Y. C., Lin-Shiau, S. Y. and Lin, J. K. (1998) Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol, 177, pp. 324-333.
11. Kong, Q., Beel, J. A. and Lillehei, K. O. (2000) A threshold concept for cancer therapy. Med Hypotheses, 55, pp. 29-35.
12. DiPietrantonio, A. M., Hsieh, T. and Wu, J. M. (1999) Activation of caspase 3 in HL-60 cells exposed to hydrogen peroxide. Biochem Biophys Res Commun, 255, pp. 477-482.
13. Girotti, A. W. (1998) Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res, 39, pp. 1529-1542.
14. Sheabar, F. Z. and Yannai, S. (1989) In vitro effects of cadmium and arsenite on glutathione peroxidase, aspartate and alanine aminotransferases, cholinesterase and glucose-6-phosphate dehydrogenase activities in blood. Vet Hum Toxicol, 31, pp. 528-531.
15. Gaetani, G. F., Ferraris, A. M., Rolfo, M., Mangerini, R., Arena, S. and Kirkman, H. N. (1996) Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. Blood, 87, pp. 1595-1599.
16. Mao, X., Stewart, A. K., Hurren, R., Datti, A., Zhu, X. Zhu, Y. et al. (2007) A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood, 110, pp. 4047-4054.
17. Margoliash, E., Novogrodsky, A. and Schejter, A. (1960) Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase. Biochem J, 74, pp. 339-348.
18. Tephly, T. R., Mannering, G. J. and Parks Jr, R. E. (1961) Studies on the mechanism of inhibition of liver and erythrocyte catalase activity by 3-amino-1,2,4-triazole (AT). J Pharmacol Exp Ther, 134, pp. 77-82.
19. Leslie, E. M., Haimeur, A. and Waalkes, M. P. (2004) Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem, 279, pp. 32700-32708.
20. Chen, G. Q., Zhu, J., Shi, X. G., Ni, J. H., Zhong, H. J. Si, G. Y. et al. (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 88, pp. 1052-1061.
21. Jing, Y., Dai, J., Chalmers-Redman, R. M., Tatton, W. G. and Waxman, S. (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 94, pp. 2102-2111.
22. Yi, J., Yang, J., He, R., Gao, F., Sang, H. Tang, X. et al. (2004) Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res, 64, pp. 108-116.
23. Sturlan, S., Baumgartner, M., Roth, E. and Bachleitner-Hofmann, T. (2003) Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood, 101, pp. 4990-4997.
24. Bachleitner-Hofmann, T., Gisslinger, B., Grumbeck, E. and Gisslinger, H. (2001) Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia?. Br J Haematol, 112, pp. 783-786.